Hidradentitis Suppurativa

Hidradenitis suppurativa has come to be associated with systemic inflammation as well as a growing list of comorbidities including acne conglobate.

Efforts are underway to identify new therapeutic methods that can offer improved outcomes for patients with hidradenitis suppurativa.

Clinical trials investigating the efficacy of biologics in treating this condition at Stage 2 and Stage 3 are growing in number and should be considered a front-line treatment option, says this expert.

Healthcare disparities exist in all fields of medicine, including dermatology. We seek to address these disparities in this article by outlining the differences in epidemiology, presentation, access and outcomes of five conditions in patients with skin of color.

Patients with hidradenitis suppurativa have a high prevalence of acne vulgaris, according to the latest research.

With one approved biologic available and many more under investigation, the future of treatment for hidradenitis suppurativa looks very promising.

Adalimumab (Humira, AbbVie) enhances both health-related quality of life and work productivity in patients with moderate-to-severe hidradenitis suppurativa, according to the results of two phase 3 clinical trials.

Patients with hidradenitis suppurativa (HS) need wound care not only after surgery, to address HS scarring and tunneling from sinus tracts; they also need ongoing wound care for lesions that might be draining, says one dermatologist.

This month, we take a look at a treatment approach to hidradenitis suppurativa, the impact of atopic dermatitis on pediatric patients and a way to prevent mycosis fungoides progression.

Hidradenitis suppurativa can impact children and teens physically and emotionally. A dermatologist explains potential differences between pediatric and adult HS.